TY - JOUR
T1 - A century past the discovery of insulin
T2 - global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries
AU - Bhutta, Zulfiqar A.
AU - Salam, Rehana A.
AU - Gomber, Apoorva
AU - Lewis-Watts, Laura
AU - Narang, Tanya
AU - Mbanya, Jean Claude
AU - Alleyne, George
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/11/13
Y1 - 2021/11/13
N2 - Type 1 diabetes is on the rise globally; however, the burden of mortality remains disproportionate in low-income and middle-income countries (LMICs). As 2021 marks 100 years since the discovery of insulin, we revisit progress, global burden of type 1 diabetes trends, and understanding of the pathogenesis and management practices related to the disease. Despite much progress, inequities in access and availability of insulin formulations persist and are reflected in differences in survival and morbidity patterns related to the disease. Some of these inequities have also been exacerbated by health-system challenges during the COVID-19 pandemic. There is a clear opportunity to improve access to insulin and related essential technologies for improved management of type 1 diabetes in LMICs, especially as a part of universal health coverage. These improvements will require concerted action and investments in human resources, community engagement, and education for the timely diagnosis and management of type 1 diabetes, as well as adequate health-care financing. Further research in LMICs, especially those in Africa, is needed to improve our understanding of the burden, risk factors, and implementation strategies for managing type 1 diabetes.
AB - Type 1 diabetes is on the rise globally; however, the burden of mortality remains disproportionate in low-income and middle-income countries (LMICs). As 2021 marks 100 years since the discovery of insulin, we revisit progress, global burden of type 1 diabetes trends, and understanding of the pathogenesis and management practices related to the disease. Despite much progress, inequities in access and availability of insulin formulations persist and are reflected in differences in survival and morbidity patterns related to the disease. Some of these inequities have also been exacerbated by health-system challenges during the COVID-19 pandemic. There is a clear opportunity to improve access to insulin and related essential technologies for improved management of type 1 diabetes in LMICs, especially as a part of universal health coverage. These improvements will require concerted action and investments in human resources, community engagement, and education for the timely diagnosis and management of type 1 diabetes, as well as adequate health-care financing. Further research in LMICs, especially those in Africa, is needed to improve our understanding of the burden, risk factors, and implementation strategies for managing type 1 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=85118891362&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(21)02247-9
DO - 10.1016/S0140-6736(21)02247-9
M3 - Review article
C2 - 34774146
AN - SCOPUS:85118891362
SN - 0140-6736
VL - 398
SP - 1837
EP - 1850
JO - The Lancet
JF - The Lancet
IS - 10313
ER -